Navigation Links
Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Date:8/22/2008

inical data suggests that combining HGS-ETR1 with chemotherapy agents could be an effective approach to the treatment of a number of malignancies, including non-small cell lung cancer," said Gilles Gallant, B. Pharm., Ph.D., Vice President, Clinical Research - Oncology, HGS. "HGS-ETR1 is the most advanced of any product in development that targets the TRAIL apoptotic pathway. The NSCLC study is one of three ongoing HGS trials designed to evaluate combinations of HGS-ETR1 with chemotherapeutic agents for the treatment of specific cancers."

About the HGS-ETR1 Proof-of-Concept Trials

The HGS-ETR1 proof-of-concept phase includes three randomized trials to evaluate its potential in combination with chemotherapy for the treatment of specific cancers:

-- Randomization and initial dosing of patients in the NSCLC study have now been completed.

-- In July 2008, HGS initiated dosing in the safety lead-in to a randomized Phase 2 trial of HGS-ETR1 in combination with Nexavar (sorafenib) in patients with advanced hepatocellular cancer, which accounts for 80-90% of all liver cancers.

-- The Company expects to have initial data available in the third quarter of 2008 from a randomized Phase 2 trial of HGS-ETR1 in combination with Velcade (bortezomib) in advanced multiple myeloma. Patients in the multiple myeloma study will continue on treatment until the progression of disease.

These three trials, taken together, will support a decision on whether to advance HGS-ETR1 to Phase 3 development. It also is possible that a sufficiently positive result from any one of the trials could lead to a Phase 3 decision for that specific indication.

About Non-Small Cell Lung Cancer

Non-small cell lung cancer accounts for approximately 75-80% of all lung cancers. It is estimated that more than 170,000 new cases and more than 160,000 deaths occur annually in the United States alone. It is currently the leading cause of cancer death in the U.S. i
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
2. ViaViente Demonstrates Cardiovascular Benefits in New Human Trial
3. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
4. ProteoTechs Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimers Disease
5. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
6. deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia
7. New Research on Pre-Eclampsia in Mice May Have Important Implications for Humans
8. Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine"
9. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
10. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
11. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... FRANCISCO, Calif. , Aug. 27, 2015 /PRNewswire/ ... therapeutics for the treatment of cancer, today announced ... member of the company,s Board of Directors, has ... led immuno-oncology at Eli Lilly and AstraZeneca, and ... first FDA approved checkpoint inhibitor, at Bristol-Myers Squibb ...
(Date:8/27/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ... therapies, today announced that it will release its year-end ... 2015 on Friday, September 4, 2015. ... call and live webcast for investors, analysts and other ...
(Date:8/27/2015)... , Aug. 27, 2015  SciClone Pharmaceuticals, Inc. (NASDAQ: ... PhD, Chief Executive Officer, will present a corporate overview and ... in New York City . , ... at 11:30 am ET at the Millennium Broadway Hotel. ... 3:00 pm ET at the St. Regis Hotel. ...
Breaking Medicine Technology:Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 2DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 3SciClone To Present At Two Investor Conferences On September 10, 2015 2
... , NANJING , China ... SCR ), a leading manufacturer and supplier of ... (also known as Endu) in China , announced today ... conference in Beijing ,dedicated to this study. The New ...
... March 18 Jeffrey B. Kindler , ... chairman of the Pharmaceutical Research and Manufacturers of America ... elected were sanofi-aventis Chief Executive Officer Christopher Viehbacher ... and John C. Lechleiter , Ph.D., Chairman, President ...
Cached Medicine Technology:Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 2Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 3Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 4Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 2Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 3Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 4Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 6Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 7Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 8
(Date:8/27/2015)... ... 27, 2015 , ... About 10 percent of mothers experienced ... Coast, killing more than 1,800 people, displacing hundreds of thousands and causing widespread ... study. , While most people don’t develop persistent depression after a major disaster ...
(Date:8/27/2015)... ... August 27, 2015 , ... StayWell, a ... Patient Education content is ICD-10 ready and available to all clients. All Krames ... code sets, which are more targeted and return a more comprehensive data set ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... In addition ... Alvernia University now offers a third doctoral program at its main campus in Reading: ... a terminal degree program designed to prepare advanced practice nurses for the highest level ...
(Date:8/27/2015)... London, UK (PRWEB) , ... ... ... Ltd and Black Swan Analysis signed a partnership agreement for quality market ... sell research reports elaborated by Black Swan Analysis. , Commenting on the ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Sunbelt® Bakery, ... high fructose corn syrup, is changing the expectation of how protein bars should taste ... indulgent taste unlike any other protein bar on the market today. , The ...
Breaking Medicine News(10 mins):Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3
... reduces the risk of heart disease. But almost everyone feels ... recent study shows that skinny people are also prone to ... factors in the genesis of various heart ailments. ,Dr. ... who headed the study, says that heart disease does not ...
... is playing havoc with the economies of,developed countries like ... of vaccinating the animals for the past three decades. ... regular basis is the best,means of preventing the spread ... joint,director of the Bangalore-based Indian Veterinary Research Institute (under,ICAR), ...
... research backed by the British government says that smoking will ... to come, surpassing the threat of even HIV. The British ... smoking will kill more people than any other disease in ... of Development Studies in Sussex, United Kingdom, says smoking and ...
... States of America has zeroed in on the culprit behind ... isolated which is said to be the cause for girls ... most widely held explanation for this is growing childhood obesity, ... were keen on the role of estrogen, a female hormone, ...
... are paranoid about heart disease. One survey said that of ... heart disease. Whenever people get to read something on heart ... worrying at times over trivial problems based on the assumption ... conducted in Austria says that chronic infections can predispose to ...
... A study conducted by Dr. Michael Brent, an associate ... St. Louis, gives us an insight into the way ... age.,These findings were presented at the annual meeting of ... San Francisco.,For years the ability of children to pick ...
Cached Medicine News:Health News:India takes on foot-and-mouth disease by vaccinating animals 2
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
Plastic. Economical. Single use. Non-Sterile....
... Portex® Blue Line® uncuffed endotracheal ... or Murphy styles, in standard ... Line® adult and pediatric uncuffed ... implant-tested polyvinyl chloride with a ...
... Portex® Blue Line® uncuffed endotracheal ... or Murphy styles, in standard ... Line® adult and pediatric uncuffed ... implant-tested polyvinyl chloride with a ...
Medicine Products: